Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development: Quantification of Emerging Protein Biomarkers

This publication has 30 references indexed in Scilit:

• Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum
  Journal of Pharmaceutical and Biomedical Analysis, 2005
• Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases
  Hepatology, 2004
• Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics
  Cancer Research, 2004
• A census of human cancer genes
  Nature Reviews Cancer, 2004
• Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges
  Toxicologic Pathology, 2004
• Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
  Clinical Chemistry, 2003
• Trends in development and approval times for new therapeutics in the United States
  Nature Reviews Drug Discovery, 2003
• Cancer Biomarker Validation: Standards and Process
  Annals of the New York Academy of Sciences, 2003
• The price of innovation: new estimates of drug development costs
  Journal of Health Economics, 2003
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
  Clinical Pharmacology & Therapeutics, 2001